Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD5 | P21918 | 1/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
| ▸ | BAD | Q92934 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5750755 | 0.87 | DRD1 (0.44) | DRD1DRD3DRD2DRD5BCL2L1 | |
| SCHEMBL5461335 | 0.81 | DRD2 (0.52) | DRD1DRD3DRD2DRD5MEN1 | |
| SCHEMBL6395035 | 0.80 | MEN1 (0.60) | DRD3DRD2MEN1KMT2APARP2 | |
| SCHEMBL5451934 | 0.79 | PNMT (0.56) | DRD1DRD3DRD2DRD5BCL2L1 | |
| SCHEMBL5467799 | 0.79 | CACNA2D1 (0.47) | DRD1DRD3DRD2DRD5MEN1 | |
| SCHEMBL5453386 | 0.77 | MEN1 (0.44) | DRD1DRD3DRD2DRD5MEN1 | |
| SCHEMBL5456128 | 0.77 | ALDH1A1 (0.59) | MEN1KMT2AL3MBTL1 | |
| SCHEMBL5456255 | 0.76 | RAB9A (0.47) | MEN1KMT2AL3MBTL1 | |
| SCHEMBL16269409 | 0.75 | DRD1 (0.47) | DRD1DRD3DRD2DRD5BCL2L1 | |
| SCHEMBL5460735 | 0.75 | CACNA2D1 (0.44) | DRD1DRD3DRD2DRD5MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1456210-B1 | PYRAZOLYL-SUBSTITUTED TRIAZOLOQUINOXALINES | JSW RES FORSCHUNGSLABOR GMBH (AT) | 2006-02-22 | — | — | EP | claimed |
| US-20050107611-A1 | Pyrazolyl-substituted triazoloquinoxalines | JSW-RESEARCH FORSCHUNGSLABOR GMBH (AT) | 2005-05-19 | — | — | US | claimed |
| EP-0745154-B1 | MULTICOMPONENT SYSTEM FOR MODIFYING, DECOMPOSING OR BLEACHING LIGNIN, LIGNIN-CONTAINING MATERIALS OR SIMILAR SUBSTANCES AND METHOD OF USING THIS SYSTEM | LIGNOZYM GMBH (DE) | 1998-09-16 | — | — | EP | claimed |
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | IONIX PHARMACEUTICALS LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| EP-1660454-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | Vernalis (R&D) Limited (GB) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005005392-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | IONIX PHARMACEUTICALS LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
| US-3987196-A | FUNGISTATS | ELI LILLY AND COMPANY (US) | 1976-10-19 | — | — | US | disclosed |
| US-3987196-A | FUNGISTATS | ELI LILLY AND COMPANY (US) | 1976-10-19 | — | — | US | disclosed |
| US-3979387-A | PROTECTION OF PLANTS FROM FOLIAR PATHOGENS | ELI LILLY AND COMPANY (US) | 1976-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | SCN1B, SCN1A, SCN10A | DRD1 1296/4885DRD3 1782/4885DRD2 1065/4885 |
| US-20050107611-A1 | Pyrazolyl-substituted triazoloquinoxalines | P2RY1, P2RX5, P2RX1 | DRD1 1326/4885DRD3 1396/4885DRD2 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.